# Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers

> **NCT01412281** · PHASE3 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 440 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Virosomal influenza vaccine (AdImmune HA Antigen)
- **BIOLOGICAL:** Virosomal influenza vaccine (CSL HA Antigen)

## Key facts

- **NCT ID:** NCT01412281
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2013-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412281, "Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01412281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*